Management of Normal GFR with Microalbuminuria
This patient has Stage 1 chronic kidney disease (CKD) and requires initiation of ACE inhibitor or ARB therapy, optimization of blood pressure control, and glycemic management if diabetic. 1, 2
Risk Stratification
With a GFR of 109 mL/min/1.73 m² (normal) and microalbuminuria of 43.6 mg/g (moderately increased albuminuria, 3-30 mg/mmol range), this patient falls into the moderate risk category for CKD progression according to KDIGO classification 3. Despite normal kidney filtration, the presence of albuminuria indicates kidney damage and defines Stage 1 CKD 4.
Primary Therapeutic Interventions
ACE Inhibitor or ARB Therapy
Start either an ACE inhibitor or ARB regardless of blood pressure status 1, 2. The 2004 diabetes nephropathy guidelines establish that:
- In patients with microalbuminuria (30-299 mg/day), ACE inhibitors or ARBs delay progression to macroalbuminuria 1
- These agents are recommended even in normotensive patients with this degree of albuminuria 2
- If one class is not tolerated, substitute the other 1
Important caveat: The 2015 guidelines note that ACE inhibitors or ARBs are NOT recommended for primary prevention in patients with normal blood pressure AND normal albumin excretion (<30 mg/g), but your patient has confirmed microalbuminuria, making treatment indicated 2.
Blood Pressure Management
Target blood pressure ≤130/80 mmHg 2. This aggressive target is critical for slowing nephropathy progression. Monitor for:
- Serum creatinine and potassium levels when using ACE inhibitors, ARBs, or diuretics 2
- Accept up to 20% increase in serum creatinine after initiating therapy—this does not indicate progressive deterioration 5
Glycemic Control (If Diabetic)
If this patient has diabetes:
- Optimize glucose control to HbA1c <7% 1, 2
- Consider SGLT-2 inhibitor therapy, as patients with GFR ≥60 mL/min/1.73 m² and moderately increased albuminuria benefit from cardiovascular and renal protection 3
- Metformin is safe at this GFR level and should be continued if already prescribed 6
Research evidence shows that even with maintained eGFR ≥60 mL/min/1.73 m², HbA1c ≥7.5% accelerates eGFR decline significantly compared to HbA1c <7.5% (-3.44 vs -1.695 mL/min/1.73 m²/year) 7.
Monitoring Strategy
Annual monitoring minimum 1, 2:
- Quantitative urinary albumin (spot urine albumin-to-creatinine ratio)
- Estimated GFR
- Serum creatinine and potassium
Every 6 months during the first year of ACE inhibitor/ARB therapy to assess treatment response 8.
Continued monitoring of albuminuria is reasonable to assess disease progression 2.
Additional Management
Lifestyle Modifications
- Sodium restriction <6 g/day (approximately 2,400 mg sodium) 9, 10
- Weight reduction if overweight (obesity increases albuminuria risk even without diabetes/hypertension) 11
- Smoking cessation 9, 10
Protein Restriction
NOT recommended at this stage. Protein restriction below 0.8 g/kg/day (the recommended daily allowance) does not alter outcomes and should only be considered with overt nephropathy 2.
Common Pitfalls to Avoid
- Do not withhold ACE inhibitor/ARB because blood pressure is normal—the indication here is albuminuria, not hypertension
- Do not panic if creatinine rises up to 20% after starting renin-angiotensin system blockade 5
- Do not use non-dihydropyridine calcium channel blockers as initial therapy—they are not more effective than placebo for slowing nephropathy progression 1
- Do not combine ACE inhibitors with ARBs—use one or the other 1
When to Refer to Nephrology
Consider nephrology referral if 2, 12:
- Continuously rising albuminuria despite treatment
- Uncertainty about kidney disease etiology
- eGFR falls below 60 mL/min/1.73 m²
- Difficult management issues (resistant hypertension, electrolyte disturbances)
This patient's normal GFR does not preclude the diagnosis of CKD—the presence of persistent albuminuria defines kidney disease regardless of filtration rate 3.